StockIQ.techCharles River Laboratories International, Inc. (CRL) Stock Analysis
Free AI-powered analysis and research for Charles River Laboratories International, Inc. stock
Sector: Healthcare
CRL snapshot
Data as of 3 Nov 2026 close. Updated daily.
Charles River Laboratories International, Inc. scores 50/100 on StockIQ's model, which reads as mixed signals overall. The price is above its 200-day average and at 88% of its 52-week range, up 96.2% over the past year. Latest reported figures show a profit margin of -6.0%, return on equity of -7.5% and revenue growth of -2.7%.
What is driving the score
- Strong Uptrend: +12
- MACD Bullish: +8
- Unprofitable (-6.0%): -15
- Weak Liquidity (1.35 Current Ratio): -5
- Negative ROE (-7.5%): -10
- High P/B (6.34): -5
- Strong Long-term Uptrend: +8
- Strong Rise (+96.2% over 1 year): +10
- Low Volume (0.4x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full CRL report
Charles River Laboratories International, Inc. (CRL) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze CRL Now →📰 Latest Update
Charles River Laboratories (CRL) Expands Virtual Control Group Use In Toxicology Studies
Fri, October 30, 2026 at 2:19 AM UTC 3 min read
Charles River Laboratories (CRL) has announced the expansion of its virtual control group capabilities in toxicology studies, enhancing the efficiency and accuracy of its research processes. This development is significant for investors as it positions CRL to deliver more reliable data, potentially attracting more clients and increasing revenue in the growing biopharmaceutical sector. The move underscores CRL's commitment to innovation, which could strengthen its competitive edge in the market.